A share price of Kura Oncology Inc [KURA] is currently trading at $6.30, up 10.72%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KURA shares have gain 11.70% over the last week, with a monthly amount drifted -2.93%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kura Oncology Inc [NASDAQ: KURA] stock has seen the most recent analyst activity on February 06, 2025, when BTIG Research downgraded its rating to a Neutral. Previously, UBS started tracking the stock with Buy rating on October 24, 2024, and set its price target to $27. On October 14, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $19 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $26 on December 22, 2023. BofA Securities initiated its recommendation with a Buy and recommended $31 as its price target on August 11, 2023. Scotiabank started tracking with a Sector Perform rating for this stock on July 27, 2023, and assigned it a price target of $10.50. In a note dated May 17, 2023, BTIG Research initiated an Buy rating and provided a target price of $31 on this stock.
Kura Oncology Inc experienced fluctuations in its stock price throughout the past year between $5.41 and $23.48. Currently, Wall Street analysts expect the stock to reach $14 within the next 12 months. Kura Oncology Inc [NASDAQ: KURA] shares were valued at $6.30 at the most recent close of the market. An investor can expect a potential return of 122.22% based on the average KURA price forecast.
Analyzing the KURA fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -2.99%, Pretax Profit Margin comes in at -2.64%, and Net Profit Margin reading is -2.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.44 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.89 points at the first support level, and at 5.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.58, and for the 2nd resistance point, it is at 6.87.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kura Oncology Inc [NASDAQ:KURA] is 8.07. Also, the Quick Ratio is 8.07, while the Cash Ratio stands at 0.57. Considering the valuation of this stock, the price to sales ratio is 8.02, the price to book ratio is 1.40.
Transactions by insiders
Recent insider trading involved Bair Teresa Brophy, Chief Legal Officer, that happened on May 19 ’25 when 1559.0 shares were sold. Chief Operating Officer, FORD KATHLEEN completed a deal on May 19 ’25 to sell 1558.0 shares. Meanwhile, Officer FORD KATHLEEN bought 1558.0 shares on May 19 ’25.
